You are here

Home » Content

HEMODİYALİZ HASTALARINDA SERUM LIPOPROTEIN (a) DÜZEYİ

SERUM LIPOPROTEIN (a) LEVELS IN HEMODIALYSIS PATIENTS

Journal Name:

  • Türk Nefroloji, Diyaliz ve Transplantasyon Dergisi

Publication Year:

  • 1995

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
İn our hemodialysis center, serum Lipoprotein (a) {Lp(a)j, Apoprotein Ai (ApoAi) and Apoprotein B (Apo B) levels were examined in 50 patients and 50 healthy controls. Of the parameters investigated by means of the nefelometer method Lp (a) was found to be high in 38% of hemodialysis patient (18 cases) and 26% of the control group (13 cases). However, there was no statistically significant difference. Serum Apo Al and Apo B levels were significantly lower in patients compared with the control group (p<0.0001). Consequently, it may be said that determination ofLp (a) level, one of the atheronegic risk indicators, may produce useful results in clinical practice.
Bookmark/Search this post with
Abstract (Original Language): 
Hemodiyaliz, mericez.imiz.deki 50 hasta ile 50 sağlıklı kişide serum lipoprotein (a) {Lp(a)}, Apoprotein Al (ApoAl) ve Apoprotein B (Apo B) düzeylerine bakıldı. Nefelometre yöntemi ile araştırılan parametrelerden Lp (a), hemodiyaliz, hasta grubunun %38'inde (18 olgu), kontrol grubunun %26' sında (13 olgu) yüksek bulundu. Fakat istatistiki yönden anlamlı fark yoktu. Serum Apo Al ve Apo B düzeyleri ise hasta grubunda kontrol grubuna göre anlamlı olarak düşüktü (p<0.0001). Sonuç olarak aterojenik risk göstergelerinden olan LP(a) düzeyinin saptanmasının, klinik uygulamada yararlı sonuçlar sağlayabileceği söylenebilir.
FULL TEXT (PDF): 
PDF icon pdf_tndt_76.pdf
  • 1
37-39
  • Turkish

REFERENCES

References: 

1. Goldberg Ap., Harter HR., Patsch W. et al. Racial differences in plasma high-density lipoproteins in patients re¬ceiving hemodialysis: A possible mechanism for accele¬rated atherosclerosis in white men. N Eng J Med 1993; 308: 1245-1252.
2. Rostand SG, Kirk KA, Rutsky EA. Relationship of coro¬nary risk factors to hemodialysis-associated ischemic he¬art disease. Kidney Int 1982; 22: 304-308.
3. Grundy SM. Management of hyperlipidemia. Kidney
Int.1990; 37; 847-853.
4. Scanu AM., Lawn RM, Berg K. Lipoprotein (a) and at¬herosclerosis. Ann Intern Med 1991; 115: 209-218.
5. Murai AT, Miyahara N., Fujimoto M., Matusda M., Ka-meyoma M. Lp(a) lipoprotein as a risk factor for coro¬nary heart disease and cerebral infarction. Atherosclero¬sis 1990; 62: 249-257.
6. Armstrong VW., Cremer P., Eberle E. et al. The associa¬tion between serum Lp(a) concentrations and angiograp-hically assessed coronary atherosclerosis Dependence on serum LDL Levels. Atherosclerosis 1986 ; 62: 249-257.
7. Sandkamp M, Funke H, Schulte H, Kahler E, Assmann G. Lipoprotein (a) is an independet risk factor for myo-cardial infarction at a young age. Clin Chem 1990 ; 36(1)
20-23.
8. Hoff HF, Beck GJ, Skibinski CL, et al. Serum Lp(a) le-' vel as a predictor of vein graft stenosis after coronary bypass surgery in patients. Circulation 1988 ; 77, 1238¬1244.
9. Kandoussi A, Cachera C, Pagniez D, Dracon M, Fruchart JC, Tacquet A. Plasma levels of lipoprotein Lp(a) is high in predialysis of hemodialysis, but not in CAPD. Kidney Int 1992; 43: 424A25.
10. Dahlen GH, Guytan JR, Airar M, Farmer JA, Kautz JA, Gotto AM. Association of level for lipoprotein Lp(a), plasma lipids, and other lipoproteins with coronary artery • dissease documented by angiography. Circulation 1986 ;
74: 758-765.
11. Rosengren A, Wilhelmsen L, Eriksson E, Risberg B, We-del H. Lipoprotein (a) and coronary heart disease: A prospective case control study in a general population sample of middle aged men. Br Med J 1990 ; 301: 1248¬1251.
12. Seed M, Happichler F, Reavelery D et al. Relation of se¬rum lipoprotein (a) concentration and apolipoprotein(a) phenotype to coronary heart disease in patients with fa¬milial hyeprcholesterolemia. N Engl J Med: 1990 ; 922: 1494-1499.
13 Nogues X, Senti M, Pedro-Botet J, Rubies-Prat J, Vidal-Barraguer F: Serum lipoprotein(a) levels in men with pe¬ripheral vascular disease. Angiology 1991; 42: 659-664.
14. Goldwasser P, Nichel MA, Collier J, et al. Prealbumin and lipoprotein (a) in hemodialysis: Relationships with patient and vascular access survival . Am J Kidney Dis
1993 ; 22 (1) 215-225.
15. Webb At, Reaveley DA, O' Donnell MO, Camor B, Seed M, Brown EA. Lipoprotein(a) in patients on maintenance haemodialysis and continuous ambulatory peritoneal di¬alysis. Nephrol Dial Transplant 1993; 8: 609-613.
16. Parra HJ, Mezdour H, Cachera C, Dracon M, Tacquet A, Fruchart JC. Lp(a) lipoprotein in patients with chronic renal failure treated by haemodialysis. Clin Chem 1987 ;
33:721.
17. Barbagallo Cm, Acerna MR, Scafidi V, Galbone A, No-tabartolo A. Increased lipoprotein (a) levels in subjects with chronic renal failure on hemodialysis. Nephron
1992; 62:471-472.
18. Okura Y, Saku K, Hirata K, et al. Serum lipoprotein (a) levels in maintenance hemodialysis patients. Nephron
1993; 65:46-50.
19. Auquet T, Senti M, Rubies-Prat J, et al. Serum lipoprote-in (a) concentration in patients with chronic renal failure receiving haemodialysis: Influence of apolipoprotein (a) genetic polymorphism. Nephrol Dial Transplant 1993; 8: 1099-1103.
20. Docci D, Baldrati L, Capponcini C, Feletti C. Serum li-poprotein (a) (Lp(a)} in haemodialysis patients. Nephrol
Dial Transplant 1994 ; 9: 733-738.
21. Appel G. Lipid abnormalities in renal disease. Kidney Int
1991; 38: 169-183.

Thank you for copying data from http://www.arastirmax.com